| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Maresin 1 (MaR1, 300 nM) decreases neutrophil migration and reactive oxygen species generation in addition to lowering IL-1β, TNF-α, IL-6, and INF-γ production [3].
|
|---|---|
| ln Vivo |
Maresin 1 (MaR1) decreases inflammation and chemotherapy-induced neuropathic pain in rats[2], inhibits TRPV1 currents in neurons in a dose-dependent manner, and blocks capsaicin (100 nM)-induced inward currents (IC50=0.49 nM). Mice are protected against acute DSS-induced colitis by maresin 1 (MaR1, 0.1, 0.3, and 1 μg/animal, ev). In an acute regimen of DSS-induced colitis, maresin 1 (0.3 and 1 μg/animal, ev) therapy dramatically reduced macroscopic damage[3].
|
| Cell Assay |
Cell Viability Assay[3]
Cell Types: Neutrophils (2 ╳105 cells/well). Tested Concentrations: 300 nM. Incubation Duration: 30 min. Experimental Results: Adherent cells are stimulated for 24 h with LPS (1 mg/ml) in the presence or absence of MaR1 (300 nM) in a final volume of 250 ml/well[3]. |
| Animal Protocol |
Animal/Disease Models: Male CD1 mice (8-10 wk of age) (colitis was induced by DSS)[3].
Doses: 0.1, 0.3, and 1 μg/animal. Route of Administration: Intraocular route one time/day from day 0 to day 7. Experimental Results: MaR1 (0.3 and 1 mg/animal) Dramatically reduces MPO levels in mouse colon tissue. |
| References | |
| Additional Infomation |
(7R,14S)-dihydroxy-(4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid is a dihydroxydocosahexaenoic acid that is (4Z,8E,10E,12Z,16Z,19Z)-docosahexaenoic acid in which the two hydroxy substituents are located at the 7R- and 14S-positions. It has a role as an anti-inflammatory agent, a human xenobiotic metabolite, a hepatoprotective agent and a specialised pro-resolving mediator. It is a dihydroxydocosahexaenoic acid and a secondary allylic alcohol. It is functionally related to an all-cis-docosa-4,7,10,13,16,19-hexaenoic acid.
Maresin 1 is a polyunsaturated dihydroxydocosahexaenoic acid that is a metabolite of docosahexaenoic acid (DHA), with potential analgesic, anti-inflammatory, and protective activities. |
| Molecular Formula |
C22H32O4
|
|---|---|
| Exact Mass |
360.23
|
| CAS # |
1268720-28-0
|
| Related CAS # |
Maresin 1-d5
|
| PubChem CID |
60201795
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
559.4±50.0 °C at 760 mmHg
|
| Flash Point |
306.2±26.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
3.81
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
26
|
| Complexity |
524
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CC/C=C\C/C=C\C[C@@H](/C=C\C=C\C=C\[C@@H](C/C=C\CCC(=O)O)O)O
|
| InChi Key |
HLHYXXBCQOUTGK-FHCQLJOMSA-N
|
| InChi Code |
InChI=1S/C22H32O4/c1-2-3-4-5-6-10-15-20(23)16-11-7-8-12-17-21(24)18-13-9-14-19-22(25)26/h3-4,6-13,16-17,20-21,23-24H,2,5,14-15,18-19H2,1H3,(H,25,26)/b4-3-,8-7+,10-6-,13-9-,16-11-,17-12+/t20-,21-/m0/s1
|
| Chemical Name |
(4Z,7R,8E,10E,12Z,14S,16Z,19Z)-7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
